About Emtora Biosciences
Emtora Biosciences is a company based in San Antonio (United States) founded in 2009. Emtora Biosciences has raised $2.5 million across 5 funding rounds from investors including Metric Medical Devices, CPRIT and UT Horizon Fund. Emtora Biosciences offers products and services including eRapa. Emtora Biosciences operates in a competitive market with competitors including Radionetics, Hinova Pharmaceuticals, Convergent Therapeutics, Nuage Therapeutics and Nymox Pharmaceutical, among others.
- Headquarter San Antonio, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.5 M (USD)
in 5 rounds
-
Latest Funding Round
$16.9 M (USD), Grant
Aug 19, 2022
-
Investors
Metric Medical Devices
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Emtora Biosciences
Emtora Biosciences offers a comprehensive portfolio of products and services, including eRapa.
Formulation of rapamycin for cancer and rare disease treatment.
Funding Insights of Emtora Biosciences
Emtora Biosciences has successfully raised a total of $2.5M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $16.9 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Emtora Biosciences
Emtora Biosciences has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Metric Medical Devices, CPRIT and UT Horizon Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Orthopedic implant systems for musculoskeletal fixation are developed.
|
Locked | Locked | Locked |
Investor details for Emtora Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Emtora Biosciences
Investment portfolio details for Emtora Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Emtora Biosciences
Detailed financials for Emtora Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Emtora Biosciences Comparisons
Peer comparison for Emtora Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Emtora Biosciences
Emtora Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Radionetics, Hinova Pharmaceuticals, Convergent Therapeutics, Nuage Therapeutics and Nymox Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Peptide-targeted radiopharmaceuticals for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Develops small molecule based drug for multiple disease treatment
|
|
| Locked | Locked | Locked |
Cancer therapeutics are developed using dual-targeted radionuclide therapy.
|
|
| Locked | Locked | Locked |
Drugs are developed for intrinsically disordered protein targets.
|
|
| Locked | Locked | Locked |
Provides research and development of novel drugs and diagnostic products for the aging population
|
|
| Locked | Locked | Locked |
Translational glycobiology research on galectin-3 inhibitors is conducted.
|
Detailed competitors of Emtora Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Emtora Biosciences
Complete news archive for Emtora Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Emtora Biosciences
Emtora Biosciences was founded in 2009 and raised its 1st funding round 3 years after it was founded.
Emtora Biosciences is headquartered in San Antonio, United States. It is registered at San Antonio, Texas, United States.
Emtora Biosciences is a funded company, having raised a total of $2.5M across 5 funding rounds to date.
Emtora Biosciences is reformulating therapies for treating cancers and other age-related disorders. They have developed eRapa which is a formulation of rapamycin that can extend life by delaying the onset of aging-related diseases such as cancer. The lead candidate is in phase I clinical trial. It is being investigated for Familial Adenomatous Polyposis (a genetic condition that increases the risk of colon cancer).
Emtora Biosciences's top competitors include Radionetics, Nuage Therapeutics and Convergent Therapeutics.
Emtora Biosciences offers eRapa.
Emtora Biosciences has 3 investors. Key investors include Metric Medical Devices, CPRIT, and UT Horizon Fund.